Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTIrreversible Protein Kinase Inhibitors: Balancing the Benefits and RisksTjeerd Barf* and Allard KapteinView Author Information Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands*Phone: +31 618 193139. E-mail, [email protected]Cite this: J. Med. Chem. 2012, 55, 14, 6243–6262Publication Date (Web):May 23, 2012Publication History Received7 March 2012Published online8 June 2012Published inissue 26 July 2012https://pubs.acs.org/doi/10.1021/jm3003203https://doi.org/10.1021/jm3003203review-articleACS PublicationsCopyright © 2012 American Chemical SocietyRequest reuse permissionsArticle Views13870Altmetric-Citations266LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Inhibition,Inhibitors,Kinase inhibitors,Monomers,Peptides and proteins Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [45]
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,944
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Activity-Based Protein Profiling: From Enzyme Chemistry to Proteomic Chemistry
Cravatt, B. F., Wright, A. T., & Kozarich, J. W. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.124125 · Cited by 1,270
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
15-Deoxy-Δ 12,14 -prostaglandin J 2 inhibits multiple steps in the NF-κB signaling pathway
Straus, D. S., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., & Glass, C. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4844 · Cited by 1,004
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.
Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A. C., Abraham, R. T., Ashendel, C. L., Zalkow, L. H., Matter, W. F., Dodge, J. A., & Grindey, G. B. (1994) · PubMed · Cited by 687
Wymann, M. P., Bulgarelli-Leva, G., Zvelebil, M. J., Pirola, L., Vanhaesebroeck, B., Waterfield, M. D., & Panayotou, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1722 · Cited by 682
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 674
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors
Cohen, M. S., Zhang, C., Shokat, K. M., & Taunton, J. (2005) · Science · doi:10.1126/science1108367 · Cited by 506
Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles
Serafimova, I. M., Pufall, M. A., Krishnan, S., Duda, K., Cohen, M. S., Maglathlin, R. L., McFarland, J. M., Miller, R. M., Frödin, M., & Taunton, J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.925 · Cited by 493
Orchestrating Redox Signaling Networks through Regulatory Cysteine Switches
Paulsen, C. E., & Carroll, K. S. (2010) · ACS Chemical Biology · doi:10.1021/cb900258z · Cited by 476
Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity
Paulsen, C. E., Truong, T. H., Garcia, F. J., Homann, A., Gupta, V., Leonard, S. E., & Carroll, K. S. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.736 · Cited by 471
Large-Scale Structural Analysis of the Classical Human Protein Tyrosine Phosphatome
Barr, A. J., Ugochukwu, E., Lee, W. H., King, O. N. F., Filippakopoulos, P., Alfano, I., Savitsky, P., Burgess-Brown, N. A., Müller, S., & Knapp, S. (2009) · Cell · doi:10.1016/j.cell.2008.11.038 · Cited by 467
Managing the challenge of chemically reactive metabolites in drug development
Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 462
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Discovery of Potent and Selective Covalent Inhibitors of JNK
Zhang, T., Inesta-Vaquera, F., Niepel, M., Zhang, J., Ficarro, S. B., Machleidt, T., Xie, T., Marto, J. A., Kim, N., Sim, T., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.11.010 · Cited by 349
Covalent Modifiers: An Orthogonal Approach to Drug Design
Potashman, M. H., & Duggan, M. E. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8008597 · Cited by 346
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
Kortemme, T., & Creighton, T. E. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0592 · Cited by 317
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., & Okazaki, O. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027797 · Cited by 251
Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234
Buhrow, S. A., Cohen, S., & Staros, J. V. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34676-3 · Cited by 231
Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays
Costello, C. M., Mah, N., Häsler, R., Rosenstiel, P., Waetzig, G. H., Hahn, A., Lu, T., Gurbuz, Y., Nikolaus, S., Albrecht, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020199 · Cited by 231
Applying Mechanisms of Chemical Toxicity to Predict Drug Safety
Guengerich, F. P., & MacDonald, J. S. (2007) · Chemical Research in Toxicology · doi:10.1021/tx600260a · Cited by 231
Huth, J. R., Mendoza, R., Olejniczak, E. T., Johnson, R. W., Cothron, D. A., Liu, Y., Lerner, C. G., Chen, J., & Hajduk, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0455547 · Cited by 228
Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226
Micronutrient Sprinkles to Control Childhood Anaemia
Zlotkin, S. H., Schauer, C., Christofides, A., Sharieff, W., Tondeur, M. C., & Hyder, S. M. Z. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020001 · Cited by 224
Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220
Carrera, A. C., Alexandrov, K., & Roberts, T. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.442 · Cited by 216
Liu, Y., Shreder, K. R., Gai, W., Corral, S., Ferris, D. K., & Rosenblum, J. S. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.009 · Cited by 209
Godin-Heymann, N., Ulkus, L., Brannigan, B. W., McDermott, U., Lamb, J., Maheswaran, S., Settleman, J., & Haber, D. A. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2387 · Cited by 203
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics
Blair, J. A., Rauh, D., Kung, C., Yun, C.-H., Fan, Q.-W., Rode, H., Zhang, C., Eck, M. J., Weiss, W. A., & Shokat, K. M. (2007) · Nature Chemical Biology · doi:10.1038/nchembio866 · Cited by 202
Oxidative stress inhibits MEKK1 by site-specific glutathionylation in the ATP-binding domain
CROSS, J. V., & TEMPLETON, D. J. (2004) · Biochemical Journal · doi:10.1042/bj20040591 · Cited by 196
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Leproult, E., Barluenga, S., Moras, D., Wurtz, J.-M., & Winssinger, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101396q · Cited by 193
IκB Kinase, a Molecular Target for Inhibition by 4-Hydroxy-2-nonenal
Ji, C., Kozak, K. R., & Marnett, L. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101266200 · Cited by 189
Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
Fitzgerald, C. E., Patel, S. B., Becker, J. W., Cameron, P. M., Zaller, D., Pikounis, V. B., O'Keefe, S. J., & Scapin, G. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb949 · Cited by 182
Targeted covalent drugs of the kinase family
Singh, J., Petter, R. C., & Kluge, A. F. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.168 · Cited by 177
The Development of HKI‐272 and Related Compounds for the Treatment of Cancer
Wissner, A., & Mansour, T. S. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800009 · Cited by 174
Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 Values
Krippendorff, B., Neuhaus, R., Lienau, P., Reichel, A., & Huisinga, W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109336751 · Cited by 173
Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides
Schirmer, A., Kennedy, J., Murli, S., Reid, R., & Santi, D. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600445103 · Cited by 169
A Cell-permeable, Activity-based Probe for Protein and Lipid Kinases
Yee, M.-C., Fas, S. C., Stohlmeyer, M. M., Wandless, T. J., & Cimprich, K. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504730200 · Cited by 166
Redox regulation of neuronal survival mediated by electrophilic compounds
Satoh, T., & Lipton, S. A. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.11.004 · Cited by 163
A clickable inhibitor reveals context-dependent autoactivation of p90 RSK
Cohen, M. S., Hadjivassiliou, H., & Taunton, J. (2007) · Nature Chemical Biology · doi:10.1038/nchembio859 · Cited by 156
Oballa, R. M., Truchon, J., Bayly, C. I., Chauret, N., Day, S., Crane, S. N., & Berthelette, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.11.044 · Cited by 150
A Structure-Guided Approach to Creating Covalent FGFR Inhibitors
Zhou, W., Hur, W., McDermott, U., Dutt, A., Xian, W., Ficarro, S. B., Zhang, J., Sharma, S. V., Brugge, J. S., Meyerson, M. M., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.02.007 · Cited by 141
Non-ATP Competitive Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791859333 · Cited by 125
Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., & Schramm, V. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300259200 · Cited by 124
Norman, B. H., Shih, C., Toth, J. E., Ray, J. E., Dodge, J. A., Johnson, D. W., Rutherford, P., Schultz, R. M., Worzalla, J. F., & Vlahos, C. J. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950619p · Cited by 123
Wu, C.-H., Coumar, M. S., Chu, C.-Y., Lin, W., Chen, Y., Chen, C.-T., Shiao, H., Rafi, S., Wang, S.-Y., Hsu, H., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100607r · Cited by 118
Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112
Singh, J., Dobrusin, E. M., Fry, D. W., Haske, T., Whitty, A., & McNamara, D. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960380s · Cited by 107
Protein Kinases as Small Molecule Inhibitor Targets in Inflammation
Gaestel, M., Mengel, A., Bothe, U., & Asadullah, K. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781696636 · Cited by 96
Irreversible Nek2 Kinase Inhibitors with Cellular Activity
Henise, J. C., & Taunton, J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200222m · Cited by 94
Chemical genetic strategy for targeting protein kinases based on covalent complementarity
Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., & Shokat, K. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111239108 · Cited by 90
Role of a cysteine residue in the active site of ERK and the MAPKK family
Ohori, M., Kinoshita, T., Yoshimura, S., Warizaya, M., Nakajima, H., & Miyake, H. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.083 · Cited by 85
Polo-like Kinases Inhibited by Wortmannin
Liu, Y., Jiang, N., Wu, J., Dai, W., & Rosenblum, J. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609603200 · Cited by 81
Irreversible Protein Kinase Inhibitors
Garuti, L., Roberti, M., & Bottegoni, G. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391705 · Cited by 76
Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology
Erve, J. C. L. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.923 · Cited by 76
Coumar, M. S., Chu, C., Lin, C., Shiao, H., Ho, Y.-L., Reddy, R., Lin, W., Chen, C.-H., Peng, Y., Leou, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000198 · Cited by 75
Discovery of selective irreversible inhibitors for EGFR-T790M
Zhou, W., Ercan, D., Janne, P. A., & Gray, N. S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.036 · Cited by 69
Lysosomal Cysteine Proteases: Structure, Function and Inhibition of Cathepsins
Roberts, R. (2005) · Drug News & Perspectives · doi:10.1358/dnp.2005.18.10.949485 · Cited by 67
Toral‐Barza, L., Zhang, W., Huang, X., McDonald, L. A., Salaski, E. J., Barbieri, L. R., Ding, W., Krishnamurthy, G., Hu, Y. B., Lucas, J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0211 · Cited by 67
Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis
Kim, K., Maderna, A., Schnute, M. E., Hegen, M., Mohan, S., Miyashiro, J. S., Lin, L., Li, E., Keegan, S., Lussier, J., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.008 · Cited by 64
Involvement of the Immune System in Idiosyncratic Drug Reactions
Zhang, X., Liu, F., Chen, X., Zhu, X., & Uetrecht, J. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-10-rv-085 · Cited by 63
Reactive Lipid Species from Cyclooxygenase-2 Inactivate Tumor Suppressor LKB1/STK11
Wagner, T. M., Mullally, J. E., & Fitzpatrick, F. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509723200 · Cited by 62
Wissner, A., Floyd, M. B., Johnson, B. D., Fraser, H. L., Ingalls, C. L., Nittoli, T., Dushin, R. G., Discafani, C. M., Nilakantan, R., Marini, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050559f · Cited by 59
Pérez, D. I., Conde, S., Pérez, C., Gil, C., Simón, D., Wandosell, F. G., Moreno, F. J., Gelpí, J. L., Luque, F. J., & Martínez, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.042 · Cited by 58
Ocaña, A., & Amir, E. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.001 · Cited by 58
Goto, M., Chow, J. C., Muramoto, K., Chiba, K., Yamamoto, S., Fujita, M., Obaishi, H., Tai, K., Mizui, Y., Tanaka, I., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156554 · Cited by 55
Molecular modeling and crystal structure of ERK2–hypothemycin complexes
Rastelli, G., Rosenfeld, R. J., Reid, R. C., & Santi, D. V. (2008) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.05.002 · Cited by 55
Carmi, C., Cavazzoni, A., Vezzosi, S., Bordi, F., Vacondio, F., Silva, C., Rivara, S., Lodola, A., Alfieri, R. R., Monica, S. L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901558p · Cited by 51
Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2
Malakhova, M., Tereshko, V., Lee, S.-Y., Yao, K., Cho, Y.-Y., Bode, A., & Dong, Z. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1347 · Cited by 48
Klüter, S., Simard, J. R., Rode, H. B., Grütter, C., Pawar, V. T., Raaijmakers, H. C. A., Barf, T. A., Rabiller, M., van Otterlo, W. A. L., & Rauh, D. (2010) · ChemBioChem · doi:10.1002/cbic.201000352 · Cited by 48
Self-citationCarmi, C., Lodola, A., Rivara, S., Vacondio, F., Cavazzoni, A., Alfieri, R. R., Ardizzoni, A., Petronini, P. G., & Mor, M. (2011) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955711797247725 · Cited by 46
Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase
Ban, H. S., Usui, T., Nabeyama, W., Morita, H., Fukuzawa, K., & Nakamura, H. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b909504g · Cited by 45
Cha, M. Y., Lee, K., Kim, J. W., Lee, C. G., Song, J. Y., Kim, Y. H., Lee, G. S., Park, S. B., & Kim, M. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901146p · Cited by 40
The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase
Cross, J. V., Foss, F. W., Rady, J. M., Macdonald, T. L., & Templeton, D. J. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-183 · Cited by 40
In Vivo Efficacy of Natural Product‐Inspired Irreversible Kinase Inhibitors
Barluenga, S., Jogireddy, R., Koripelly, G. K., & Winssinger, N. (2010) · ChemBioChem · doi:10.1002/cbic.201000205 · Cited by 36
Bell, I. M., Stirdivant, S. M., Ahern, J. D., Culberson, J. C., Darke, P. L., Dinsmore, C. J., Drakas, R. A., Gallicchio, S. N., Graham, S. L., Heimbrook, D. C., et al. (2005) · Biochemistry · doi:10.1021/bi0500628 · Cited by 35
The functional role of cysteine residues for c-Abl kinase activity
Leonberg, A. K., & Chai, Y.-C. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9501-y · Cited by 33
Kinetic mechanism and ATP‐binding site reactivity of p38γ MAP kinase
Fox, T., Fitzgibbon, M. J., Fleming, M. A., Hsiao, H.-M., Brummel, C. L., & Su, M. S. S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01488-x · Cited by 28
A Chemical Genetic Approach for Covalent Inhibition of Analogue-Sensitive Aurora Kinase
Koch, A., Rode, H. B., Richters, A., Rauh, D., & Hauf, S. (2012) · ACS Chemical Biology · doi:10.1021/cb200465c · Cited by 27
Kim, B. H., Lee, J., Seo, J. H., Lee, H. Y., Ryu, S. Y., Ahn, B. W., Lee, C., Hwang, B. Y., Han, S., & Kim, Y. S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.069 · Cited by 25
Synthesis and biological evaluation of p38α kinase-targeting dialkynylimidazoles
Li, J., Kaoud, T. S., Laroche, C., Dalby, K. N., & Kerwin, S. M. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.094 · Cited by 24
Evans, E. K., Tester, R. W., Aslanian, S., Chaturvedi, P., Mazdiyasni, H., Ponader, S., Tesar, B. M., Sheets, M. P., Nacht, M., Stiede, K., et al. (2011) · Blood · doi:10.1182/blood.v118.21.3485.3485 · Cited by 20
Muramoto, K., Goto, M., Inoue, Y., Ishii, N., Chiba, K., Kuboi, Y., Omae, T., Wang, Y. J., Gusovsky, F., & Shirota, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168583 · Cited by 19
Synthesis and Activity of C11-Modified Wortmannin Probes for PI3 Kinase
Yuan, H., Luo, J., Field, S. J., Weissleder, R., Cantley, L. C., & Josephson, L. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049714f · Cited by 18
Vereb, G., Balla, A., Gergely, P., Wymann, M. P., Gülkan, H., Suer, S., & Heilmeyer, L. M. G. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00006-1 · Cited by 14
Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors
Qin, J., Dhondi, P., Huang, X., Aslanian, R. G., Fossetta, J. D., Tian, F., Lundell, D. J., & Palani, A. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200238g · Cited by 14
Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Lin, K., Dubrovskiy, A., Lee, K., Martin, T. S., Karp, R., Zhu, Z., Niu, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c189 · Cited by 12
Scoggins, R. M., Summerfield, A. E., Stein, R. A., Guyer, C. A., & Staros, J. V. (1996) · Biochemistry · doi:10.1021/bi952909d · Cited by 10
Liu, Y., Wu, J., Weissig, H., Betancort, J. M., Gai, W. Z., Leventhal, P. S., Patricelli, M. P., Samii, B., Szardenings, A. K., Shreder, K. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.045 · Cited by 6
Research works printed but not linked: 5
- Powis G., 1994, Cancer Res., 54, 2419
- Wood E. R., 2008, Proc. Natl. Acad. Sci. U.S.A., 105, 2772
- Brigdes A. J., 2000, Chem. Rev., 101, 2541
- Advani, R.; Sharman, J.; Smith, S.; Boyd, T.; Grant, B.; Kolibaba, K.; Furman, R.; Buggy, J.; Loury, D.; Hedrick, E.; Izumi, R.; Hamdy, A.; Fowler, N.The Btk Inhibitor PCI-32765 Is Highly Active and Well Tolerated in Patients with Relapsed/Refractory B Cell Malignancies: Final Results from a Phase I Study. Presented at the 11th International Conference on Malignant Lymphoma (ICML), Lugano, Switzerland, June 15–18, 2011.
- Petter, R.Targeted Covalent Kinase Inhibitors: AVL 292 as a Potent, Irreversible and Selective Inhibitor of Btk. Presented at the 5th Anglo-Swedish Medicinal Chemistry Symposium (ASMC), Åre, Sweden, March 20–23, 2011.
Cited by
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Liu, Q., Sabnis, Y., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 652
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Metadata
- Authors
- Barf, T., & Kaptein, A.
- Affiliations
- Drug Discovery Unit, Covalution Pharma BV, Ravenstein, The Netherlands
- Corresponding author
- Barf, Tjeerd
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-06-08
- Volume
- 55
- Issue
- 14
- Pages
- 6243-6262
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2057079741
- Cited by
- 331
- References
- 108
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 21 · 2023: 17 · 2022: 9 · 2021: 30 · 2020: 38 · 2019: 26 · 2018: 22 · 2017: 38 · 2016: 32 · 2015: 22 · 2014: 25 · 2013: 14 · 2012: 7
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- kinase inhibitors, covalent inhibitors, drug development, benefits and risks, kinase-targeted therapy
- MeSH terms
- Animals, Cell Line, Humans, Protein Kinases, Risk, Structure-Activity Relationship, Time Factors, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.